Literature summary extracted from
Sundy, J.S.; Ganson, N.J.; Kelly, S.J.; Scarlett, E.L.; Rehrig, C.D.; Huang, W.; Hershfield, M.S.
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout (2007), Arthritis Rheum., 56, 1021-1028.
Application
EC Number |
Application |
Comment |
Organism |
---|
1.7.3.3 |
medicine |
the enzyme might be useful in the treatment of patients with refractory gout, overview |
Sus scrofa |
Protein Variants
EC Number |
Protein Variants |
Comment |
Organism |
---|
1.7.3.3 |
additional information |
the recombinantly expressed porcine enzyme, with a C-terminal sequence from baboon uricase, is applicated to patients with refractory gout, due to a mutation in the uricase gene, by intravenous injection in a PEG-bound form, pharmacokinetics and pharmacodynamics, safety, and efficacy of the treatment in a clinical trial, overview |
Sus scrofa |
Organism
EC Number |
Organism |
UniProt |
Comment |
Textmining |
---|
1.7.3.3 |
Sus scrofa |
P16164 |
- |
- |
Synonyms
EC Number |
Synonyms |
Comment |
Organism |
---|
1.7.3.3 |
uricase |
- |
Sus scrofa |